Ivabradine Anpharm

Ivabradine, the active ingredient in Ivabradine Anpharm, is a selective If channel inhibitor presented as an oral formulation for oral administration. It is indicated for the management of chronic heart failure (NYHA class II–III) with reduced ejection fraction and for stable angina pectoris in adult patients.

GNH USA supplies Ivabradine Anpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand consistently.

Ivabradine is used to manage cardiovascular conditions that involve elevated heart rate. - Chronic heart failure (NYHA class II–III) with reduced ejection fraction: reduces heart rate, improving ventricular filling and symptoms. - Stable angina pectoris: lowers heart rate, decreasing myocardial oxygen demand and relieving angina. - Coronary artery disease with symptomatic angina: helps improve exercise capacity by controlling heart rate.

Common Side Effects: - Bradycardia: resting heart rate may fall below the intended range. - Visual disturbances (phosphenes): transient luminous phenomena, especially in low‑light conditions. - Headache: mild to moderate intensity, often transient. - Dizziness or vertigo: related to reduced heart rate or blood pressure changes. - Fatigue or general weakness: may accompany heart‑rate lowering. - Blurred vision: occasional, usually resolves with continued use.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other serious arrhythmias. - Severe hypotension leading to syncope. - High‑grade atrioventricular block. - Severe visual impairment or persistent phosphene phenomena. - Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating therapy, consider the following precautions: - Cardiac monitoring: assess baseline heart rate and rhythm. - Hepatic impairment: avoid or adjust dose in severe liver disease. - Sick sinus syndrome or atrioventricular block: contraindicated unless a pacemaker is present. - Concomitant CYP3A4 inhibitors: avoid strong inhibitors to prevent excess exposure. - Pregnancy and lactation: safety not established; use only if clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ivabradine may interact with several medicines. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase ivabradine plasma levels. - Co‑administration with other heart‑rate lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia. - Other If channel inhibitors (e.g., ranolazine): additive effect on heart‑rate reduction. Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - QT‑prolonging drugs: monitor ECG for additive prolongation. - Antihypertensives: enhanced hypotensive effect may occur, requiring blood pressure monitoring.